These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 10926348)

  • 1. Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.
    Johnson SA
    Clin Pharmacokinet; 2000 Jul; 39(1):5-26. PubMed ID: 10926348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleoside analogues in the treatment of haematological malignancies.
    Johnson SA
    Expert Opin Pharmacother; 2001 Jun; 2(6):929-43. PubMed ID: 11585009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of purine nucleoside analogues.
    Plunkett W; Gandhi V
    Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S67-74. PubMed ID: 9137959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies.
    Johnson SA; Thomas W
    Hematol Oncol; 2000 Dec; 18(4):141-153. PubMed ID: 11135355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications.
    Robak T; Korycka A; Kasznicki M; Wrzesien-Kus A; Smolewski P
    Curr Cancer Drug Targets; 2005 Sep; 5(6):421-44. PubMed ID: 16178817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular and clinical pharmacology of fludarabine.
    Gandhi V; Plunkett W
    Clin Pharmacokinet; 2002; 41(2):93-103. PubMed ID: 11888330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.
    Robak T; Lech-Maranda E; Korycka A; Robak E
    Curr Med Chem; 2006; 13(26):3165-89. PubMed ID: 17168705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of cladribine, fludarabine and pentostatin on nucleotide metabolism in T- and B-cell lines.
    Wilson PK; Szabados E; Mulligan SP; Christopherson RI
    Int J Biochem Cell Biol; 1998 Jul; 30(7):833-42. PubMed ID: 9722988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of fludarabine in hematological malignancies.
    Montillo M; Ricci F; Tedeschi A
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1141-61. PubMed ID: 17020450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond hairy cell: the activity of cladribine in other hematologic malignancies.
    Sigal DS; Miller HJ; Schram ED; Saven A
    Blood; 2010 Oct; 116(16):2884-96. PubMed ID: 20634380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purine analogues in the management of lymphoproliferative diseases.
    Johnson SA
    Clin Oncol (R Coll Radiol); 1996; 8(5):289-96. PubMed ID: 8934048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Older and new purine nucleoside analogs for patients with acute leukemias.
    Robak P; Robak T
    Cancer Treat Rev; 2013 Dec; 39(8):851-61. PubMed ID: 23566572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog.
    Faderl S; Gandhi V; Keating MJ; Jeha S; Plunkett W; Kantarjian HM
    Cancer; 2005 May; 103(10):1985-95. PubMed ID: 15803490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.
    Cheson BD; Vena DA; Barrett J; Freidlin B
    J Clin Oncol; 1999 Aug; 17(8):2454-60. PubMed ID: 10561309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
    Galmarini CM; Mackey JR; Dumontet C
    Leukemia; 2001 Jun; 15(6):875-90. PubMed ID: 11417472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Nucleoside analogues--new drugs for the treatment of lymphatic cancers].
    Itälä M; Remes K
    Duodecim; 2001; 117(2):162-9. PubMed ID: 12092367
    [No Abstract]   [Full Text] [Related]  

  • 17. 2-Chloro-2'-deoxyadenosine (2CdA) biochemical aspects of antileukemic efficacy.
    Fabianowska-Majewska K; Wyczechowska D
    Acta Pol Pharm; 1996; 53(4):231-9. PubMed ID: 9415193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies.
    Robak T; Korycka A; Robak E
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):23-38. PubMed ID: 18221024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders.
    Brogden RN; Sorkin EM
    Drugs; 1993 Oct; 46(4):652-77. PubMed ID: 7506651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse and beneficial immunological effects of purine nucleoside analogues.
    Dighiero G
    Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S75-81. PubMed ID: 9137960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.